Drug Trial Radar · NCT03705234
A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular Disease
Last checked: Nov 19, 2026Latest source record: May 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
16,124
Actual
Start
Oct 30, 2018
Primary completion
Oct 2026
Study completion Dec 2049
Sponsor
- Lead sponsor
- University of OxfordAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- The TIMI Study Group; Novartis Pharmaceuticals
- First posted
- Oct 15, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
ORION-4 is a research study coordinated by the University of Oxford and co-sponsored by The University of Oxford and Novartis (Protocol: CTSU\_MDCO-PCS-17-01 (CKJX839B12301)). The study aims to find out if a new cholesterol-lowering injection (inclisiran) safely lowers the risk of heart attacks and strokes in people who have already had one of these conditions, or who have had an operation or procedure to treat blocked arteries.
Conditions
- Atherosclerotic Cardiovascular Disease
Interventions
InclisiranDrug
Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.
PlaceboDrug
Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for injection).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with a major adverse cardiovascular event (MACE)Time frame: Median follow-up of 5-years
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
TIMI Study Group
Boston, Massachusetts
CTSU, University of Oxford
Oxford, Oxfordshire, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.